| Body mass index (BMI), BMI change, and overall survival in patients with SCLC and NSCLC: a pooled analysis of the international lung cancer consortium D Shepshelovich, W Xu, L Lu, A Fares, P Yang, D Christiani, J Zhang, ... Journal of Thoracic Oncology 14 (9), 1594-1607, 2019 | 104 | 2019 |
| Subtypes of EGFR-and HER2-mutant metastatic NSCLC influence response to immune checkpoint inhibitors SCM Lau, AF Fares, LW Le, KM Mackay, S Soberano, SW Chan, E Smith, ... Clinical Lung Cancer 22 (4), 253-259, 2021 | 56 | 2021 |
| BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer R Shi, SN Martins Filho, M Li, A Fares, J Weiss, NA Pham, O Ludkovski, ... Lung Cancer 146, 78-85, 2020 | 36 | 2020 |
| Clinical and pathological discrepancies and cardiovascular findings in 409 consecutive autopsies AF Fares, J Fares, GF Fares, JA Cordeiro, MA Nakazone, PM Cury Arquivos brasileiros de cardiologia 97, 449-455, 2011 | 32 | 2011 |
| Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma WH da Costa, IW da Cunha, AF Fares, SM Bezerra, L Shultz, DA Clavijo, ... Urologic Oncology: Seminars and Original Investigations 36 (5), 243. e1-243. e8, 2018 | 29 | 2018 |
| The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung … M Jiang, AF Fares, D Shepshelovich, P Yang, D Christiani, J Zhang, ... Lung Cancer 152, 58-65, 2021 | 28 | 2021 |
| Value assessment of oncology drugs using a weighted criterion‐based approach DA Ezeife, F Dionne, AF Fares, ELR Cusano, R Fazelzad, W Ng, ... Cancer 126 (7), 1530-1540, 2020 | 19 | 2020 |
| Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma WH da Costa, AF Fares, SM Bezerra, MA Morini, LA de Toledo Benigno, ... Urologic Oncology: Seminars and Original Investigations 37 (1), 78-85, 2019 | 19 | 2019 |
| ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases AF Fares, BH Lok, T Zhang, M Cabanero, SCM Lau, T Stockley, D Patel, ... Lung Cancer 146, 350-354, 2020 | 18 | 2020 |
| Clinical-pathological discrepancies in critically ill patients with difficult premortem diagnoses AF Fares, PM Cury, SM Lobo Revista Brasileira de Terapia Intensiva 23, 442-447, 2011 | 15 | 2011 |
| Association between duration of smoking abstinence before non-small-cell lung cancer diagnosis and survival: a retrospective, pooled analysis of cohort studies AF Fares, Y Li, M Jiang, MC Brown, ACL Lam, R Aggarwal, S Schmid, ... The Lancet Public Health 8 (9), e691-e700, 2023 | 11 | 2023 |
| Smoking cessation (SC) and lung cancer (LC) outcomes: A survival benefit for recent-quitters? A pooled analysis of 34,649 International Lung Cancer Consortium (ILCCO) patients. AF Fares, M Jiang, P Yang, DC Christiani, C Chen, P Brennan, J Zhang, ... Journal of Clinical Oncology 38 (15_suppl), 1512-1512, 2020 | 11 | 2020 |
| Assessing therapy response in patient-derived xenografts J Ortmann, L Rampášek, E Tai, AS Mer, R Shi, EL Stewart, C Mascaux, ... Science Translational Medicine 13 (620), eabf4969, 2021 | 10 | 2021 |
| Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model AF Fares, DV Araujo, V Calsavara, AO Saito, MN Formiga, AA Dettino, ... ecancermedicalscience 13, 2019 | 9 | 2019 |
| Concurrent chemoradiation with or without durvalumab in elderly patients with unresectable stage III NSCLC: safety and efficacy SCM Lau, M Ryan, J Weiss, AF Fares, M Garcia, S Schmid, S Kuang, ... JTO Clinical and Research Reports 2 (12), 100251, 2021 | 7 | 2021 |
| Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy SCM Lau, C Poletes, LW Le, KM Mackay, AF Fares, PA Bradbury, ... Lung Cancer 156, 76-81, 2021 | 7 | 2021 |
| EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models SN Martins-Filho, J Weiss, NA Pham, Q Li, M Cabanero, A Fares, ... Lung Cancer 145, 144-151, 2020 | 5 | 2020 |
| P48. 05 is relapse-free survival at 2-years an appropriate surrogate for overall survival at 5-years in EGFR-mutated resected NSCLC? M Garcia, S Schmid, K Hueniken, L Zhan, K Balaratnam, K Khan, A Fares, ... Journal of Thoracic Oncology 16 (10), S1107-S1108, 2021 | 4 | 2021 |
| Accounting for EGFR Mutations in Epidemiologic Analyses of Non–Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data S Schmid, M Jiang, MC Brown, A Fares, M Garcia, J Soriano, M Dong, ... Cancer Epidemiology, Biomarkers & Prevention 31 (3), 679-687, 2022 | 2 | 2022 |
| Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil AF Fares, LA Fadul, B Benetton, ML Nogueira, M Lanza, DV Araújo ecancermedicalscience 15, 2021 | 2 | 2021 |
Natasha LeighlMedical Oncology, Princess Margaret在 uhn.ca 的电子邮件经过验证
